Format

Send to

Choose Destination
Drugs. 2018 Jun;78(8):823-831. doi: 10.1007/s40265-018-0912-8.

Management of Embolic Stroke of Undetermined Source (ESUS).

Author information

1
Department of Cardiology, University Hospital Tübingen, Otfried-Müller-Straße 10, 72076, Tübingen, Germany. tobias.geisler@med.uni-tuebingen.de.
2
Department of Neurology and Stroke, University Hospital Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.

Abstract

According to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification, embolic stroke of undetermined source (ESUS) has refined the old definition of cryptogenic stroke. More sophisticated criteria and a well-defined diagnostic workup point out the embolic nature of this disease. Because ESUS is associated with a high stroke recurrence, a clear risk prediction and management is of utmost importance to improve prognosis. To date, standard pharmacotherapy consists of antiplatelet drugs and statins. This review attempts to provide an overview on the diagnostic criteria, prognosis, and current clinical trials evaluating the value of direct oral anticoagulants for secondary prevention after ESUS.

PMID:
29737498
DOI:
10.1007/s40265-018-0912-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center